Gustavo
@gusviani
Professor/ Researcher/ Data Analyst/ Radiation Oncologist 📩 Get the latest studies and insights—subscribe here: http://gusviani.substack.com
You are in history...you are history! Great Jannik! You are the CHAMPION🏆 The first Italian to win @Wimbledon🎾 The KING 👑 Thanks @janniksin 🇮🇹
@CJTsaiMDPhD you'll be updated right away! It's a promise!!! 😉 And hopefully as soon as possible! 🤞
ENRT vs. MDT in Prostate Cancer: Promising Results from PEACE V–STORM Trial!!! 🚨@OncoAlert 🎯 Objective: Assess if ENRT is superior to MDT for PET-detected pelvic nodal oligorecurrences in prostate cancer 🏥 Methods: • Ph2, RCT, 196 👥, 21 centers • Eligibility: ≥18 y/o,…
📢 We'd be the proudest and happiest of all!!! #STARTNEWERA phase II trial is giving us huge satisfaction 💪 ✅ Fast and effectiveness! We believe that #SAbR is the key to to tackling LA-NSCLC 😉 @PaolaAnselmo7 @gusviani @jryckman3
@CJTsaiMDPhD it's great to have your like of our trial!👉doi.org/10.1016/j.ijro… 🤞 Coming soon the updated publication with protocol attached!!! @PaolaAnselmo7 @gusviani
👉Localised setting 1️⃣ #POPART trial:predictors toxicity & oncological outcomes salvage #SAbR prostate bed 👉#oligo-R hormone-sensitive 2️⃣ #PERSIAN trial:ADT-APA 🆚 ADT-APA ➕ #SAbR 3️⃣ substudy #RADIOSA trial:liquid biopsy molecular characterization Great session #GU #ESTRO25
1️⃣10-y #FASTFORWARD early-stage breast 2️⃣ #SKAGEN 50Gy/25 vs 40Gy/15 loco-regional RT high-risk breast 3️⃣10-y ultra #HYPO RT localised prostate 👉In the two most common settings standard RT moved or is moving to hypo-RT instead of conv-RT! Phase 3 trials pratic change 👌